Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients

AIDS. 2015 Oct 23;29(16):2213-4. doi: 10.1097/QAD.0000000000000835.

Authors

Kuan-Yin Lin¹, Chien-Ching Hung

Affiliation

¹ aDivision of Infectious Diseases, Department of Internal Medicine, Taipei City Hospital, Kun-Ming Branch bDepartment of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei cDepartment of Medical Research, China Medical University Hospital dChina Medical University, Taichung, Taiwan.

PMID: 26544585
DOI: 10.1097/QAD.0000000000000835

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / adverse effects*
Anti-Bacterial Agents / metabolism
Anti-Bacterial Agents / therapeutic use
Anti-HIV Agents / adverse effects*
Anti-HIV Agents / metabolism
Anti-HIV Agents / therapeutic use
Bacterial Infections / complications
Bacterial Infections / drug therapy
Darunavir / adverse effects*
Darunavir / metabolism
Darunavir / therapeutic use
Drug Hypersensitivity / epidemiology
Drug Hypersensitivity / pathology
Drug Interactions*
Drug-Related Side Effects and Adverse Reactions*
HIV Infections / complications
HIV Infections / drug therapy
Humans
Retrospective Studies
Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects*
Trimethoprim, Sulfamethoxazole Drug Combination / metabolism
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

Anti-Bacterial Agents
Anti-HIV Agents
Trimethoprim, Sulfamethoxazole Drug Combination
Darunavir